Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Nami Kurozumi
Binimetinib, a Novel MEK1/2 Inhibitor, Exerts Anti-Leukemic Effects Under Inactive Status of PI3Kinase/Akt Pathway
International Journal of Hematology
Hematology
Related publications
Icaritin, a Novel FASN Inhibitor, Exerts Anti-Melanoma Activities Through IGF-1R/STAT3 Signaling
Oncotarget
Oncology
Combination of EGFR and MEK1/2 Inhibitor Shows Synergistic Effects by Suppressing EGFR/HER3-dependent AKT Activation in Human Gastric Cancer Cells
Molecular Cancer Therapeutics
Cancer Research
Oncology
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy--Response
Clinical Cancer Research
Cancer Research
Oncology
Exogenous Hydrogen Sulfide Exerts Proliferation, Anti-Apoptosis, Migration Effects and Accelerates Cell Cycle Progression in Multiple Myeloma Cells via Activating the Akt Pathway
Oncology Reports
Medicine
Cancer Research
Oncology
The Marine-Derived Kinase Inhibitor Fascaplysin Exerts Anti-Thrombotic Activity
Marine Drugs
Drug Discovery
Galangin Ameliorates Cardiac Remodeling via the MEK1/2-ERK1/2 and PI3K-AKT Pathways
Journal of Cellular Physiology
Clinical Biochemistry
Cell Biology
Physiology
Sanbai Melon Seed Oil Exerts Its Protective Effects in a Diabetes Mellitus Model via the Akt/GSK-3β/Nrf2 Pathway
Journal of Diabetes Research
Endocrinology
Metabolism
Diabetes
Antitumor Activities of JTP-74057 (GSK1120212), a Novel MEK1/2 Inhibitor, on Colorectal Cancer Cell Lines in Vitro and in Vivo
International Journal of Oncology
Cancer Research
Oncology
Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
